JAMA
Original Investigation
April 6, 2024
Richard M.ÌýMartin,ÌýBM, BS, PhD; Emma L.ÌýTurner,ÌýPhD; Grace J.ÌýYoung,ÌýMSc; ChrisÌýMetcalfe,ÌýPhD; Eleanor I.ÌýWalsh,ÌýMSc; J. AtheneÌýLane,ÌýPhD; Jonathan A. C.ÌýSterne,ÌýPhD; SianÌýNoble,ÌýPhD; PeterÌýHolding,ÌýMSc; YoavÌýBen-Shlomo,ÌýMBBS, PhD; Naomi J.ÌýWilliams,ÌýPhD; NoraÌýPashayan,ÌýMD, PhD; Mai NgocÌýBui,ÌýPhD; Peter C.ÌýAlbertsen,ÌýMD; Tyler M.ÌýSeibert,ÌýMD, PhD; Anthony L.ÌýZietman,ÌýMD; JonÌýOxley,ÌýMD; JanÌýAdolfsson,ÌýMD; Malcolm D.ÌýMason,ÌýMD; GeorgeÌýDavey Smith,ÌýDSc; David E.ÌýNeal,ÌýMD; Freddie C.ÌýHamdy,ÌýMD; Jenny L.ÌýDonovan,ÌýPhD; CAP Trial Group
is active quiz
has multimedia
JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011
This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.
JAMA Oncology
Comment & Response
January 20, 2022
NoraÌýPashayan,ÌýMD, PhD; Paul D. P.ÌýPharoah,ÌýMBBS, PhD
JAMA Oncol. 2022; 8(3):483-484. 10.1001/jamaoncol.2021.7311
ÁñÁ«ÊÓƵ Network Open
Original Investigation
Oncology
March 11, 2021
ThomasÌýCallender,ÌýMBChB, MSc; MarkÌýEmberton,ÌýMBBS, MD; StephenÌýMorris,ÌýPhD; Paul D. P.ÌýPharoah,ÌýBM, BCh, PhD; NoraÌýPashayan,ÌýMD, PhD
open access
ÁñÁ«ÊÓƵ Netw Open. 2021; 4(3):e2037657. 10.1001/jamanetworkopen.2020.37657
This decision analytical model uses a hypothetical cohort of men in England to evaluate whether magnetic resonance imaging before biopsy for prostate cancer screening is associated with improvements in benefit-harm and cost-effectiveness profiles compared with biopsy-first screening.
JAMA Oncology
Comment & Response
January 17, 2019
NoraÌýPashayan,ÌýMD, PhD; Paul D. P.ÌýPharoah,ÌýMBBS, PhD
JAMA Oncol. 2019; 5(3):428-429. 10.1001/jamaoncol.2018.6504
JAMA Oncology
Original Investigation
July 5, 2018
NoraÌýPashayan,ÌýMD, PhD; SteveÌýMorris,ÌýPhD; Fiona J.ÌýGilbert,ÌýMBChB, FRCR; Paul D. P.ÌýPharoah,ÌýMBBS, PhD
open access
has multimedia
JAMA Oncol. 2018; 4(11):1504-1510. 10.1001/jamaoncol.2018.1901
This cost-effectiveness study uses a life-table model of a hypothetical cohort of 364 500 women to evaluate the cost-effectiveness and benefit to harm ratio of risk-stratified screening for breast cancer.